Moderna

The exceptionally low pricing power score of 8/100 for Moderna directly correlates with its current operational and financial struggles.

While the company initially commanded strong pricing for its COVID-19 vaccine during the pandemic's peak, the subsequent market saturation, emergence of competing products, and declining emergency demand have severely eroded its ability to dictate prices.

This erosion is starkly illustrated by the profound negative margins, including a TTM Operating Margin of -203.5%, a TTM Net Margin of -185.0%, and a TTM FCF Margin of -270.8%.

These figures indicate that the company is not only unable to extract premium prices but is also currently selling below its operational costs, failing to cover expenses and generate any positive cash flow from its core operations.

Such a situation is highly concerning and signifies a complete lack of leverage in pricing negotiations, forcing the company to potentially liquidate inventory or absorb significant losses to maintain market presence, far from the robust pricing power seen in companies with patented, irreplaceable products.